Sudha Chaturvedi

Sudha Chaturvedi, Ph.D.

Director, Mycology Laboratory
Clinical Associate Professor, Biomedical Sciences, School of Public Health, University at Albany
Ph.D., Medical Microbiology (1990), Faculty of Medicine, University of Delhi, Delhi, India
Postdoctoral training: Fungal pathogenesis and parasite cell biology, University of Cincinnati & Yale University
(518) 474-7563

Research Interests

Dr. Sudha Chaturvedi is the Director of the Mycology Laboratory, which serves as the comprehensive reference facility for fungal diagnostics for all NYSDOH-licensed clinical laboratories, including hospitals, academic medical centers, county health departments, and commercial laboratories.

Since 2016, the Mycology Laboratory also serves as an Antibiotic Resistance Lab Network Laboratory for the Centers for Disease Control and Prevention (CDC), assessing the prevalence of drug-resistant Candida spp. in the Northeast.

Some of the laboratory's major undertakings include innovations in fungal diagnostics, antifungal testing, drug-resistance mechanisms, fungal pathogenesis, and molecular epidemiology.

The laboratory utilizes state of the art technologies including: 

  • Next-generation sequencing in clinical mycology
  • Molecular methods for fungal detection and identification
  • Application of protein-based technologies for yeast and mold identification
  • The study of the antifungal drug-resistance trends, mechanisms of action, and detection methods
  • Analysis of population-level trends of invasive fungal infection 
  • Development of vertebrate and invertebrate model systems for fungal pathogens

The Mycology Laboratory collaborates with federal and industry partners to improve the knowledge of fungal infection and well-being in our communities. The laboratory houses a fungal culture collection repository, an outstanding resource for assay development, distribution, and sale. 

Major research accomplishments

Development of the rapid and sensitive molecular assay for the direct detection of multidrug-resistant Candida auris from patient samples
Candida auris, a multidrug-resistant yeast, emerged in the United States in 2016, causing an unprecedented outbreak in several states. The Mycology Laboratory developed a rapid molecular test to directly detect C. auris from patient samples. The rapid test played a crucial role in combating the C. auris outbreak. The rapid test was subsequently adopted by the CDC, all seven AR Lab Network Laboratories, along with several public health and clinical laboratories in the US. In 2018, the Council of State and Territorial Epidemiologists (CSTE) used our molecular test as the marker for the culture-independent case definition of patients colonized with C. auris. We transitioned the test from a manual to a high-throughput BD MAX platform. The rapid test is now included in the CDC’s proficiency testing program for all seven regional labs, with 100% accuracy, a testament to consistency across the board. Collaborations are also underway to bring about a point-of-care testing device to be used at the patient’s bedside or physician’s office.

Detection of pan-resistant isolates of Candida auris from New York
The Mycology Laboratory aided NYS epidemiologists in characterizing pan-resistant isolates of C. auris from three NY patients. This is the first report of the identification of pan-resistant strains of C. auris from the US. The active surveillance following identification led to no further spread of these strains in the affected healthcare facilities.

C. auris outbreak: Impact and Lessons Learned
The efforts of the Mycology Laboratory in assay development, resistance detection, genotyping, use of combined swab of nares/axilla/groin, quantification of C. auris from patient skin and healthcare environment demonstrating extensive colonization of biotic (patient) and abiotic (healthcare objects) surfaces resulted in publication, which was later recognized as worthy of an accompanying commentary. APHL featured our exemplary work on C. auris in the 2019 summer issue of Lab Matters

Select Publications
Zhu Y, Kilburn S, Kapoor M, Chaturvedi S, Shaw KJ, Chaturvedi V. In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak. Antimicrob Agents Chemother. 2020; 64 (11): DOI: 10.1128/AAC.01124-20
Rossow J, Ostrowsky B, Adams E, Greenko J, McDonald R, Vallabhaneni S, Forsberg K, Perez S, Lucas T, Alroy K, Slifka KJ, Walters M, Jackson BR, Quinn M, Chaturvedi S, Blog D. Factors associated with Candida auris colonization and transmission in skilled nursing facilities with ventilator units, New York, 2016-2018. Clin Infect Dis. 2020; DOI: 10.1093/cid/ciaa1462
O"Brien B, Liang J, Chaturvedi S, Jacobs JL, Chaturvedi V. Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations. Lancet Microbe. 2020; 1 (5): e193-e194. DOI: 10.1016/S2666-5247(20)30090-2
Yan L, Xia K, Yu Y, Miliakos A, Chaturvedi S, Zhang F, Chen S, Chaturvedi V, Linhardt RJ. Unique Cell Surface Mannan of Yeast Pathogen Candida auris with Selective Binding to IgG. ACS Infect Dis. 2020; 6 (5): 1018-1031. DOI: 10.1021/acsinfecdis.9b00450
Zhu Y, O'Brien B, Leach L, Clarke A, Bates M, Adams E, Ostrowsky B, Quinn M, Dufort E, Southwick K, Erazo R, Haley VB, Bucher C, Chaturvedi V, Limberger RJ, Blog D, Lutterloh E, Chaturvedi S. Laboratory Analysis of an Outbreak of Candida auris in New York from 2016 to 2018: Impact and Lessons Learned. J Clin Microbiol. 2020; 58 (4): e01503-19. DOI: 10.1128/JCM.01503-19
O'Brien B, Chaturvedi S, Chaturvedi V. In Vitro Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak. 2020; DOI: 10.1128/AAC.02195-19
Ostrowsky B, Greenko J, Adams E, Quinn M, O'Brien B, Chaturvedi V, Berkow E, Vallabhaneni S, Forsberg K, Chaturvedi S, Lutterloh E, Blog D. Candida auris Isolates Resistant to Three Classes of Antifungal Medications - New York, 2019. MMWR Morb Mortal Wkly Rep. 2020; 69 (1): 6-9. DOI: 10.15585/mmwr.mm6901a2
Leach L, Russell A, Zhu Y, Chaturvedi S, Chaturvedi V. A Rapid and Automated Sample-to-Result Candida auris Real-Time PCR Assay for High-Throughput Testing of Surveillance Samples with the BD Max Open System. J Clin Microbiol. 2019; 57 (10): DOI: 10.1128/JCM.00630-19
Leach L, Zhu Y, Chaturvedi S. Development and Validation of a Real-Time PCR Assay for Rapid Detection of Candida auris from Surveillance Samples. J Clin Microbiol. 2018; 56 (2): e01223-17. DOI: 10.1128/JCM.01223-17
Full publication listing